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a b s t r a c t
PEGylated recombinant human endostatin (M2ES) exhibited prolonged serum half-life and enhanced
antitumor activity when compared with endostatin. A non-clinical study was performed to evaluate
the toxicokinetics and safety of M2ES in rhesus monkeys. After intravenous (IV) infusions of M2ES at a
dose level of 3, 10, and 30 mg/kg in rhesus monkeys, the concentration–time curves of M2ES were best
fitted to a non-compartment model, and area under the curve (AUC) was positively correlated with
the dosage. M2ES had a tendency to accumulate in vivo following successive IV infusions. Serum anti-
M2ES IgG antibodies were generated quickly during IV administration, and the antibody level in serum
did not significantly decrease after four-week recovery period. Animals administered IV infusions twice
weekly (M2ES at 10 or 30 mg/kg body weight per day) for 3 months developed mild or moderate
vacuolation of proximal tubule epithelial cell in proximal convoluted tubule of kidney, but this
adverse-effect was reversible. In summary, M2ES was well tolerated and did not cause any serious
toxicity. These pre-clinical safety data contribute to the initiation of the ongoing clinical study.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Endostatin, a C-terminal proteolytic fragment of collagen XVIII,
is a potent endogenous tumor angiogenesis inhibitor (O’Reilly
et al., 1997). It has been widely reported that endostatin impairs
angiogenesis and tumor progression through inhibiting endothelial
cell proliferation, migration, and tube formation (Abdollahi et al.,
2005; O’Reilly et al., 1997; Ribatti, 2008; Shi et al., 2007; Song
et al., 2012; Sudhakar et al., 2003; Zhuo et al., 2010). However, endo-
statin is easily degraded by proteolytic enzymes, and rapidly cleared
by the kidneys (Hu et al., 2008; Nie et al., 2006). Therefore, after IV
infusion, endostatin presents a short half-life in vivo (Hu et al., 2008;
Song et al., 2005). Polyethylene glycol (PEG), a low-toxic, low-
immunogenic, low-antigenic polyether compound, was used as a
carrier and listed in the US FDA’s Inactive Ingredient Guide
(http://www.accessdata.fda.gov/scripts/cder/IIG/getiigWEB.cfm).http://dx.doi.org/10.1016/j.yrtph.2014.05.019
0273-2300/ 2014 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.o
⇑ Corresponding authors. Fax: +86 10 67014758 (B. Li). Address: Cancer Biology
Laboratory, School of Life Sciences, Tsinghua University, Beijing 100084, China. Fax:
+86 10 6279 4691 (Y. Luo).
E-mail addresses: libo@nifdc.org.cn (B. Li), yluo@mail.tsinghua.edu.cn (Y. Luo).
1 These authors contributed equally to this work.This polymer has been widely researched for pharmaceutical and
biotechnical applications, particularly themodifications of peptides
and proteins (Fiume et al., 2012; Harris and Chess, 2003; Jevsevar
et al., 2010; Roberts et al., 2002). Several studies have reported that
PEGylation protects proteins from proteolytic enzymes, and
increases the molecular mass of proteins, thus increasing its stabil-
ity, decreasing its kidney filtration, and prolonging its half-life
in vivo (Harris and Chess, 2003; Veronese and Pasut, 2005). Nowa-
days, many therapeutic proteins, such as insulin, interleukin II,
human growth hormone, interferon, and granulocyte-colony stimu-
lating factor (G-CSF) have been PEGylated (Becker et al., 2012;
Caparrotta and Evans, 2013; George et al., 2008; Harris and Chess,
2003; Kang and Lee, 2013; Sivasubramanian et al., 2011). These
results provide the impetus to develop the PEGylated recombinant
human endostatin (M2ES). Mono-PEGlaylation of recombinant
human endostatin improved antitumor activity, and prolonged
serum half-life, compared with endostatin (Nie et al., 2006).
However, there are no reports on the evaluation of toxicokinetics
and safety of PEGylated endostatin in non-human primates.
In this study, the pre-clinical toxicokinetics and safety of M2ES
were evaluated preceding the initiation of a phase I clinical trial.rg/licenses/by-nc-nd/3.0/).
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All studies were carried out in National Center for Safety Evalu-
ation of Drugs (Beijing, China) in accordance with Good Laboratory
Practice (GLP) (China Food and Drug Administration (CFDA), 2003),
and Preclinical Safety Evaluation of Biotechnology-Derived Phar-
maceuticals (ICH S6, 2012) (Federal Register, 18 May 2012, Vol.
77, No. 97, p. 29665–6). Animal procedures were approved by
the Institutional Animal Care and Use Committee of National Insti-
tute for Food and Drug Control, China, which had passed the
accreditation of Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC). Animal care and
welfare were performed according to Guide for the Care and Use
of Laboratory Animals.
2.1. Test substance
The homologous between human endostatin and rhesus mon-
key endostatin is 96%. Test articles were produced by fermentation
at commercial scale. M2ES (PEGylated recombinant human endo-
statin, Escherichia coli BL21(DE3) strain) was obtained from Protgen
Ltd. (Beijing, China). M2ES was purified by two steps. (1) Dissolve
the inclusions; (2) anionic column purification. PEGylation of
recombinant human endostatin (rhES) Endostatin solution (10–
20 mg/ml, pH 5.2–5.3) was added NaBH3CN (20 mM), and then
added PEG2000 (PEG: protein = 1.5:1) at 37 C for 4 h. M2ES purity
was measured by SDS–PAGE, High-performance liquid chromatog-
raphy (HPLC) (Agilent 1100) and capillary zone electrophoresis
(CZE) (Beckman P/ACE 5000). The purity of M2ES was more than
98% (Fig. 1). M2ES activity was measure by endothelial cell migra-
tion assay. The activity of M2ES was more than 310 U/ml. Dose lev-
els include 7.5, 10.0, 12.5, 15 mg/m2 and dosing duration is 2 h, Test
articles were given twice/weekly by syringe pump (Syringe Pump
TE-331, Terufusion, Terumo, Tokyo, Japan). Dose volume was
2 mL/kg and delivery speed was 3 mL/min. Twice/weekly dosingFig. 1. SDS–PAGE (12%) analysis of the purified M2ES. The purified M2ES stained
with comassie blue. Lane 1: protein marters; lane 2: M2ES (15 lg). The purity of
M2ES is 99.6%. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)was selected mainly based on previous data, which demonstrated
that M2ES was intravenously administrated into nude mice twice
a week exhibiting highest anti-tumor efficacy (unpublished data).
2.1.1. The stability of M2ES
The stability of M2ES was determined by both acceleration test
and long term stability test. Acceleration test results: The appear-
ance, pH value, purity, content, activity, sterility test and endotoxin
inspection of M2ES did not show significant difference at 37 C for
3 months and at 25 C for 6 months. Long term stability test: The
appearance, pH value, purity, content, activity, sterility test and
endotoxin inspection of M2ES did not show significant difference
at 2–8 C for 18 months. The working solutions were directly
produced from a stock solution. M2ES had good stability at
2–8 C and stable time was more than 18 months.
2.1.2. Dose selection
Dose confirmation and homogeneity testing was conducted by
the sponsor Protgen Ltd. Three concentrations (1.5, 5.0, and
15.0 mg/mL) of M2ES were used in this study. Dose design was
followed by Case by Case principle in this study according to the
guidance of ICH S6. Low-dose group: The optimum dose of phar-
macodynamics ranges was from 3 mg/kg to 6 mg/kg in mice
(Table 1). Based on mouse–monkey body surface area conversion
standards, we selected 3 mg/kg as low-dose group in monkey. This
dosage is about 3.23 times as much as proposed human clinical
dose (24.6 mg/60 kg). High-dose group: In three-month repeated-
dose toxicity study, kidney injury in rats was observed in the dose
of 75 mg/kg (Table 2) (37.2 times as much as human). In addition,
considering drug costs (time and financial for production) we
selected 30 mg/kg as high-dose group (equal to 75 mg/kg in rat).
This dosage is about 32.61 times as much as human, which
provides enough dosage space for clinical trial design. Middle-dose
group: According to three times ratio principle, we selected 10 mg/
kg as middle-dose group.2.2. Animals and animal husbandry
Rhesus monkeys (breeding colony, 12 males, 12 females) were
from purchased from Laboratory Animal Research Center, Acad-
emy of Military Medical Sciences (Laboratory animal production
license: SCXK(army) 2002-001), Beijing, China. Both cynomolgus
monkeys and rhesus macaques are widely used animals for testing
of biological drugs. Since rhesus macaques were used in pre-clini-
cal study of MES (Pro-drug of M2ES) and pharmacokinetics (PK)
study of M2ES before the initial of this study. To compare the
toxicity reaction of M2ES with that of MES in the same species,
rhesus macaques were selected. Rhesus monkeys were 2- to
3-year-old and with body weights of 2.70–3.95 kg (males) and
3.85–4.70 kg (females) at study initiation. They were randomized
into four groups (3 animals/sex/group) based on individual body
weight. The animals were maintained under condition of 16–26 
C, 40–70% relative humidity. Each monkey was provided with
standard monkey keeping diet, and fruits.
2.3. Toxicokinetics
In the three-month repeat-dose toxicity study, toxicokinetics
before dosing, and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96 h after the start
(day 1), and the end (day 87) IV infusions of M2ES at 3, 10, 30 mg/
kg were evaluated in rhesus monkeys. A competition ELISA assay
was used to detect the concentration of M2ES in serum samples
from the animals. Briefly, ELISA plates (Costar, Cambridge, MA,
USA) were coated with 100 ll of endostatin rabbit polyclonal anti-
body (2 lg/hole) containing solutions at 4 C overnight. The plates
were washed three times with 0.1% Tween20-PBS and then 5%
BSA-PBS confining liquids were added at 37 C for 2 h. After the
plates were washed, 100 ll of serum samples (1:100 diluted serum
and biotin–endostatin (50 ng/mL), 1:1.8) were added, and incu-
bated at 37 C for 1.5 h. After the plates were washed, 50 ll
1:1000 diluted HPR-avidin were added, and incubated at 37 C
for 1 h. The plates were then washed, and 100 ll of 3,30,50,50-tetra-
methyl benzidine (TMB) (Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, MD, USA) was added. When 2 M H2SO4 was added
to stop the reaction, the plates were measured at 450 nm with
an ELISA reader (Spectra Max Plus, Molecular Devices, Sunnyvale,
CA, USA).
2.4. Anti-M2ES antibodies
In the three-month repeat-dose toxicity study with four-week
recovery. ELISA assay was used to detect the generation of anti-
M2ES antibodies in serum samples from the animals. Briefly, ELISA
plates (Costar, Cambridge, MA, USA) were coated with 100 ll of
M2ES or sheep-anti-monkey IgG containing solutions at 4 C over-
night. The plates were washed six times and added 200 ll blocking
solution at 37 C for 1 h. After the plates were washed, 100 ll of
serum samples (1:50 diluted), 100 ll diluent solution (negative
control) and 100 ll control serum samples (1:50 diluted) (positive
control) were added, and incubated at 37 C for 1.5 h. After the
plates were washed, 100 ll 1:10000 diluted HPR-sheep-anti-mon-
key IgG were added, and incubated at 37 C for 1 h. The plates were
washed and 100 ll of 3,30,50,50-tetramethyl benzidine (TMB)
(Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD, USA)
was added. When 2 M H2SO4 was added to stop the reaction, the
plates were measured at 450 nm with an ELISA reader (Spectra
Max Plus, Molecular Devices, Sunnyvale, CA, USA). OD450nm value
(3 mg/kg, 10 mg/kg and 30 mg/kg group) was greater than 2.1
times OD450nm value (0 mg/kg group) setting as positive.
2.5. Three-month repeat-dose toxicity study with four-week recovery
In the GLP-compliant three-month repeat-dose toxicity study
with four-week recovery (according to the guidelines of
repeated-dose toxicity study in China, recovery period were
generally from two to four weeks in three-month repeated-dose
toxicity study. Considering M2ES exhibits long half-life and strong
immunogenicity, we selected 4-week recovery period in this
study), rhesus monkeys were assigned to four groups (3 animals/
sex/group). Animals were administered saline or 3, 10, or 30 mg/
kg M2ES twice weekly (twice/weekly dosing was selected mainly
based on previous data, which demonstrated that M2ES was intra-
venously administrated into nude mice twice a week exhibiting
highest anti-tumor efficacy) by IV infusions. All main study ani-
mals (2 animals/sex/group) were terminated on day 90 (three days
after the end infusion). To evaluate the reversibility of any poten-
tial treatment-related side-effects, recovery animals (1 animal/
sex/group) were terminated on day 118 (after four-week recovery
period). In addition, according to the guidance of Preclinical Safety
Evaluation of Biotechnology-Derived Pharmaceuticals (ICH S6,
2012), standard 3 month toxicology studies in non-rodents use
3–4 animals/sex/group with 2 animals/sex for recovery. Since
pre-clinical toxicokinetics and safety study of M2ES in rhesus mon-
keys were performed in 2006, 2 animals/sex/group (main study)
and 1 animal/sex/group (recovery) could satisfy CFDA require-
ments at that time. We used 2 animals/sex/group (main study)
and 1 animal/sex/group (recovery) in this study. Considering the
requirements of (ISH S6, 2012), CFDA would revise the guideline,
and the animal requirements will be amended into at least 3 ani-
mals/sex/group (main study) and 2 animal/sex/group (recovery).
The following safety parameters were measured: clinical obser-
vations, body weight, food consumption, urine analysis, body tem-
perature, electrocardiography (ECG) (Electrocardiograph CardiMax
FX-7102, Fukuda Denshi Co., Ltd., Japan), hematology (white blood
cell count (WBC), red blood cell count (RBC), hemoglobin concen-
tration (HGB), hematocrit (HCT), mean corpuscular volume
(MCV), mean cell hemoglobin (MCH), mean cell hemoglobin con-
centration (MCHC), platelets (PLT), mean platelet volume (MPV),
reticulocyte (Retic), neutrophiles (Neut), lymphocytes (Lymph),
monocytes (Mono), eosinophiles (Eos), basophiles (Baso), pro-
thrombin time (PT), activated partial thromboplastin time (APTT))
(Bayer ADVIA 120 (Bayer; Bayer Corp., Tarrytown, NY, USA) and
Sysmex CA-1500 (Sysmex Corporation, Kobe, Japan)), Serum
CD4+, CD8+ levels and CD4+/CD8+ (FACSCalibur, BD Biosciences,
Table 2
Kidney – three-month repeat-dose toxicity study with 4-week recovery.
Time Groups (mg/kg) Kidney (rat)
Left Right
Wt (g) RWt (g/100 g) Wt (g) RWT (g/100 g)
Administration 0 1.742 ± 0.060 0.323 ± 0.040 1.779 ± 0.116 0.331 ± 0.048
3 1.768 ± 0.325 0.322 ± 0.041 1.739 ± 0.293 0.318 ± 0.043
15 1.742 ± 0.114 0.314 ± 0.024 1.748 ± 0.114 0.315 ± 0.028
75 1.611 ± 0.097 0.322 ± 0.023 1.614 ± 0.097 0.322 ± 0.022
4-Week recovery 0 1.531 ± 0.246 0.326 ± 0.022 1.538 ± 0.180 0.329 ± 0.020
3 1.553 ± 0.285 0.313 ± 0.022 1.606 ± 0.285 0.324 ± 0.019
15 1.568 ± 0.112 0.336 ± 0.018 1.589 ± 0.119 0.341 ± 0.024
75 1.799 ± 0.065 0.407 ± 0.045** 1.774 ± 0.148 0.399 ± 0.020**
Wt (g): absolute weight; RWt (g/kg): relative kidney weight. SD: mean ± standard deviation.
** P < 0.01.
Table 1
Anti-tumor efficacy of M2ES intravenous injection on H22 bearing mouse (BALB/c).
Parameters M2ES (groups)
Control 3 mg/kg 6 mg/kg 12 mg/kg
Tumor weight (g) 2.00 ± 1.04 1.81 ± 0.94 1.19 ± 0.39 2.10 ± 1.48
IR (%) 0 7 40.6 0
IR: inhibition rate, SD: mean ± standard deviation.
* P < 0.05.
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San Jose, CA, USA), clinical chemistry (glucose (GLU), blood urea
nitrogen (BUN), creatinine (CRE), cholestero (CHO), triglyceride
(TG), potassium (K+), sodium (Na+), chlorine (Cl) (Ca2+, K+, Na+,
and Cl were commonly used parameters in clinic. Since electro-
lyte instrument (Rapidchem744, Bayer, MA, USA) used in this
study could only detect K+, Na+ and Cl, we did not detect Ca2+),
alanine aminotransferase (ALT), aspartate aminotransferase (AST),
total protein (TP), albumin (ALB), total bilirubin (TBIL), alkaline
phosphatase (ALP), lactate dehydrogenase (LDH), creatine kinase
(CK)) (Hitachi 7060 (Hitachi Ltd., Tokyo, Japan) and Bayer Rapid-
chemTM 744 (Bayer Corp., Tarrytown, NY, USA)), organ weight
(heart, liver, spleen, lung, kidney, brain, adrenal gland, thymus,
thyroid gland, testis, epididymis, uterus, ovary).
After necropsy, the following organs and tissues were histopa-
thologically examined: brain, spinal cord, heart, aorta, lung, liver,
kidneys, spleen, pancreas, stomach, duodenum, jejunum, ileum,
Fig. 2. Toxicokinetics of M2ES. Plasma profiles between 0 and 96 h after 0.5 h infusions of M2ES in low dose (3 mg/kg), mid dose (10 mg/kg), and high dose (30 mg/kg)
treatment groups (n = 6). Plasma profiles determined at the start of the study (day 1) are shown in (A), and plasma profiles determined at the end of the study (day 87) are
shown in (B). Plasma profiles between 0 and 96 h after 0.5 h infusions of the M2ES in low dose (3 mg/kg) (C), mid dose (10 mg/kg) (D), and high dose (30 mg/kg) (E) treatment
groups (n = 6). Plasma profiles determined at the start of the study (day 1) are shown by solid triangle (N), and plasma profiles determined at the end of the study (day 87) are
shown by the solid square (j).
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colon, rectum, cecum, testes, epidymides, prostatic gland, ovaries,
uterus, vagina, urinary bladder, hypophysis cerebri, thyroid, sali-
vary gland, adrenals, sciatic nerve, muscle, mesenteric lymph
nodes, thymus, mammary gland (female), sternum and injection
sites (muscle, skin, blood vessels).
2.6. Statistical analysis
Long-term toxicity study of M2ES in rats (10 animals/sex/group)
showed that there were no significant gender differences in RBC,
Hb, and LDH values after M2ES treatment. In addition, no published
paper reported that endostatin could cause significant gender dif-
ferences in both hematology and clinical chemistry tests. Consider-
ing the number of rhesus monkeys (3 animals/sex/group), it was
difficult to performed statistical analysis in single gender (male
vs. female). We did not design experiment which related potential
sex specific effect in this study. For statistical analysis, the data was
performed using ANOVA followed by the Dunnett’s test for com-
parison of differences between group mean values. The level of sta-
tistics significance for all tests were p < 0.05 level.
3. Results
3.1. Toxicokinetics
Toxicokinetics after the start of (day 1) M2ES IV infusions at 3,
10, and 30 mg/kg were investigated in rhesus monkeys. The con-
centration–time curves of M2ES were best fitted to a non-compart-
ment model. Peak concentration (Cmax) was reached after 0.5 h, and
peak time (Ctime) gradually decreased in a time-dependent manner
in all animals (Fig. 2A, Table 3). The AUC(0–96) of M2ES (day 1) was
9.2 ± 3.7, 36.1 ± 7.4, and 180.6 ± 38.4 lg h/mL at the 3 dose levels,
respectively (Table 3). The ratio of dose and the corresponding ratio
of AUC(0–96) were 1:3.3:10 and 1:3.9:19.6, respectively, indicating
that AUC of M2ES is positively correlated with the dosage.
Similarly, toxicokinetics after the end point of (day 87) IV M2ES
administrations at 3, 10, and 30 mg/kg were determined in
Table 3
Pharmocokinetic parameters of M2ES following a 0.5 h IV infusion in rhesus monkeys at the start (day 1) of the study.
Parameters Unit 3 mg/kg 10 mg/kg 30 mg/kg
Mean S.D. Mean S.D. Mean S.D.
Tmax h 0.5 0.0 0.6 0.2 0.7 0.3
Cmax lg/mL 2.6 0.7 8.5 2.1 38.8 10.4
T1/2 h 8.5 9.8 29.0 7.9 30.4 8.2
AUCall lg h/mL 9.2 3.7 36.1 7.4 180.6 38.4
AUC0-inf lg h/mL 9.9 4.7 38.4 8.2 192.3 42.5
CL mL/h/kg 349.9 125.6 270.6 57.2 162.8 37.0
AUMClast lg h2/mL 70.8 84.2 483.9 139.6 2503.7 437.2
AUMC0-inf lg h2/mL 130.2 205.0 806.7 345.9 4177.0 1152.6
MRTlast h 6.2 5.0 13.3 2.5 14.0 0.8
MRT0-inf h 9.3 10.4 20.6 7.1 21.6 2.8
Vss mL/kg 2332.4 1611.8 5466.9 1950.0 3471.1 727.7
SD: mean ± standard deviation.
Table 4
Pharmocokinetic parameters of M2ES following a 0.5 h IV infusion in rhesus monkeys at the end (day 87) of the study.
Parameters Unit 3 mg/kg 10 mg/kg 30 mg/kg
Mean SD Mean SD Mean SD
Tmax h 0.5 0.0 0.5 0.0 0.6 0.2
Cmax lg/mL 2.9 0.7 10.7 3.0 45.8 11.5
T1/2 h 24.4 19.4 20.6 4.9 63.6 30.2
AUCall lg h/mL 27.2 20.0 117.5 55.2 278.7 110.3
AUC0-inf lg h/mL 31.6 25.2 141.6 72.8 354.4 159.0
CL mL/h/kg 146.2 96.9 101.6 84.9 102.2 55.1
AUMClast lg h2/mL 682.5 797.3 4076.9 2561.4 5809.8 3382.5
AUMC0-inf lg h2/mL 1297.8 1484.8 7164.6 4890.6 20529.3 12398.4
MRTlast h 18.9 12.7 30.5 13.4 20.2 3.8
MRT0-inf h 30.6 22.4 48.6 25.7 54.5 18.7
Vss mL/kg 2869.4 1925.1 3200.3 612.5 5036.2 1720.2
SD: mean ± standard deviation.
Table 5
Antibody – three-month repeat-dose toxicity study with 4-week recovery.
Time Groups
M2ES
(3 mg/kg)
M2ES
(10 mg/kg)
M2ES
(30 mg/kg)
Pretreatment (day 0) 0/6 0/6 0/6
Treatment (day 14) 1/6 4/6 1/6
Treatment (day 30) 6/6 6/6 5/6
Treatment (day 90) 6/6 6/6 5/6
4-Week recovery (day 14) 2/2 2/2 2/2
4-Week recovery (day 28) 2/2 2/2 2/2
a/b: First number indicates positive animal number; second number indicates total
animal number.
Table 6
Clinical observations – three-month repeat-dose toxicity study with 4-week recovery.
Parameters Groups
Control M2ES (3 mg/kg) M2ES
(10 mg/kg)
M2ES
(30 mg/kg)
Liquid feces 0/6 1/6 0/6 0/6
Abnormal injection site 0/6 0/6 0/6 0/6
Rectocele 1/6 0/6 0/6 0/6
a/b: First number indicates positive animal number; second number indicates total
animal number.
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Fig. 3. Body weights of rhesus monkeys in the three-month repeat-dose toxicity study with four-week recovery.
Table 7
Hematology – three-months repeat-dose toxicity study with 4-week recovery.
Parameters Time M2ES (groups)
Control 3 mg/kg 10 mg/kg 30 mg/kg
WBC (109/L) Acclimation period (day 16) 8.15 ± 2.69 8.03 ± 3.92 7.35 ± 2.54 6.54 ± 2.81
Acclimation period (day 44) 10.55 ± 3.28 8.42 ± 1.74 8.17 ± 3.71 6.73 ± 1.57
Treatment (day 30) 8.76 ± 3.71 10.13 ± 4.46 9.42 ± 2.12 7.37 ± 1.31
Treatment (day 60) 8.09 ± 3.24 7.72 ± 2.20 8.25 ± 2.89 6.74 ± 0.73
Treatment (day 90) 6.90 ± 3.19 7.67 ± 3.60 6.77 ± 2.07 6.25 ± 1.17
4-Week recovery 9.83 ± 1.92 9.72 ± 0.17 9.26 ± 3.90 9.48 ± 0.67
RBC (1012/L) Acclimation period (day 16) 5.46 ± 0.43 5.43 ± 0.32 5.34 ± 0.39 5.56 ± 0.47
Acclimation period (day 44) 5.55 ± 0.26 5.27 ± 0.30 5.31 ± 0.39 5.46 ± 0.31
Treatment (day 30) 5.50 ± 0.32 5.15 ± 0.22 5.37 ± 0.43 5.41 ± 0.42
Treatment (day 60) 5.08 ± 0.35 4.99 ± 0.19 5.07 ± 0.42 5.15 ± 0.48
Treatment (day 90) 4.89 ± 0.37 4.18 ± 0.24** 4.26 ± 0.36** 4.44 ± 0.28
4-Week recovery 5.02 ± 0.24 5.03 ± 0.25 5.08 ± 0.85 5.44 ± 0.39
HGB (g/L) Acclimation period (day 16) 134 ± 13 138 ± 10 135 ± 9 138 ± 11
Acclimation period (day 44) 132 ± 9 129 ± 8 130 ± 9 132 ± 8
Treatment (day 30) 131 ± 11 128 ± 9 131 ± 10 129 ± 10
Treatment (day 60) 126 ± 11 129 ± 7 128 ± 11 129 ± 10
Treatment (day 90) 123 ± 12 108 ± 9* 107 ± 9* 110 ± 6
4-Week recovery 128 ± 12 136 ± 11 127 ± 23 139 ± 11
HCT (%) Acclimation period (day 16) 40.6 ± 3.6 42.3 ± 3.1 41.4 ± 2.2 43.1 ± 3.9
Acclimation period (day 44) 42.6 ± 2.5 41.4 ± 2.8 42.0 ± 2.3 43.5 ± 2.3
Treatment (day 30) 43.9 ± 3.1 42.7 ± 2.3 43.9 ± 3.2 44.1 ± 3.6
Treatment (day 60) 40.7 ± 3.6 40.8 ± 2.5 41.2 ± 3.8 41.5 ± 3.8
Treatment (day 90) 37.6 ± 4.0 32.9 ± 2.8 32.9 ± 3.0 34.5 ± 2.5
4-Week recovery 40.5 ± 3.4 42.5 ± 3.0 39.7 ± 6.3 44.2 ± 3.2
MCV (fL) Acclimation period (day 16) 74.5 ± 3.1 77.9 ± 2.5 77.8 ± 3.4 77.4 ± 1.1
Acclimation period (day 44) 76.8 ± 2.3 78.6 ± 3.4 79.3 ± 3.4 79.6 ± 1.2
Treatment (day 30) 79.9 ± 1.9 82.8 ± 1.4 82.0 ± 3.6 81.6 ± 1.1
Treatment (day 60) 80.0 ± 3.0 81.8 ± 3.4 81.4 ± 3.6 80.8 ± 1.1
Treatment (day 90) 76.8 ± 3.8 78.7 ± 3.8 77.3 ± 3.9 77.6 ± 2.1
4-Week recovery 80.6 ± 2.9 84.4 ± 1.7 78.1 ± 0.8 81.2 ± 0.0
MCH (pg) Acclimation period (day 16) 24.5 ± 0.9 25.4 ± 0.8 25.3 ± 0.9 24.9 ± 0.6
Acclimation period (day 44) 23.9 ± 0.7 24.5 ± 0.9 24.5 ± 0.5 24.1 ± 0.5
Treatment (day 30) 23.9 ± 0.8 24.8 ± 0.9 24.5 ± 0.6 24.0 ± 0.6
Treatment (day 60) 24.8 ± 0.9 25.8 ± 1.1 25.3 ± 1.0 25.1 ± 0.9
Treatment (day 90) 25.2 ± 1.0 25.7 ± 1.2 25.2 ± 1.0 24.8 ± 0.5
4-Week recovery 25.4 ± 1.1 27.0 ± 0.7 24.9 ± 0.3 25.6 ± 0.2
MCHC (g/L) Acclimation period (day 16) 330 ± 8 326 ± 1 325 ± 8 322 ± 8
Acclimation period (day 44) 311 ± 8 312 ± 5 310 ± 13 303 ± 9
Treatment (day 30) 299 ± 5 299 ± 7 299 ± 9 294 ± 7
Treatment (day 60) 310 ± 4 315 ± 6 312 ± 8 311 ± 10
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Table 7 (continued)
Parameters Time M2ES (groups)
Control 3 mg/kg 10 mg/kg 30 mg/kg
Treatment (day 90) 328 ± 5 327 ± 10 326 ± 9 320 ± 10
4-Week recovery 315 ± 3 320 ± 2 319 ± 7 315 ± 2
PLT (109/L) Acclimation period (day 16) 376 ± 54 436 ± 41 389 ± 81 398 ± 57
Acclimation period (day 44) 381 ± 62 411 ± 37 348 ± 62 400 ± 53
Treatment (day 30) 371 ± 55 395 ± 43 374 ± 62 383 ± 28
Treatment (day 60) 384 ± 103 419 ± 56 338 ± 56 295 ± 143
Treatment (day 90) 286 ± 71 350 ± 53 294 ± 91 321 ± 54
4-Week recovery 274 ± 30 368 ± 42 326 ± 24 340 ± 43
MPV (fL) Acclimation period (day 16) 6.4 ± 0.6 6.3 ± 0.3 6.4 ± 0.5 6.4 ± 0.6
Acclimation period (day 44) 5.9 ± 0.5 6.1 ± 0.4 6.2 ± 0.5 6.1 ± 0.6
Treatment (day 30) 6.8 ± 0.6 6.8 ± 0.5 7.1 ± 0.5 6.9 ± 0.7
Treatment (day 60) 6.8 ± 0.6 6.7 ± 0.3 6.9 ± 0.5 7.9 ± 2.3
Treatment (day 90) 7.6 ± 1.7 7.8 ± 0.7 7.8 ± 1.1 7.4 ± 1.0
4-Week recovery 6.5 ± 0.3 6.7 ± 0.9 7.1 ± 0.8 7.0 ± 1.3
Retic (%) Acclimation period (day 16) 1.5 ± 0.6 1.5 ± 0.5 1.6 ± 0.5 1.4 ± 0.5
Acclimation period (day 44) 1.2 ± 1.0 0.7 ± 0.9 1.0 ± 0.7 1.0 ± 1.0
Treatment (day 30) 1.3 ± 0.3 1.1 ± 0.2 1.3 ± 0.6 1.0 ± 0.2
Treatment (day 60) 1.3 ± 0.5 1.1 ± 0.2 1.4 ± 0.3 1.3 ± 0.3
Treatment (day 90) 1.3 ± 0.4 2.0 ± 1.1 2.1 ± 1.1 2.0 ± 0.7
4-Week recovery 1.9 ± 0.1 1.6 ± 0.0 2.1 ± 0.3 1.9 ± 0.4
Neut (%) Acclimation period (day 16) 47.1 ± 19.8 48.8 ± 13.6 47.8 ± 6.0 47.8 ± 12.2
Acclimation period (day 44) 58.2 ± 15.2 51.6 ± 9.8 49.3 ± 13.2 45.5 ± 8.5
Treatment (day 30) 34.9 ± 11.6 50.5 ± 9.8 42.9 ± 10.5 42.5 ± 13.8
Treatment (day 60) 33.7 ± 12.5 38.5 ± 5.9 39.8 ± 7.5 35.9 ± 11.0
Treatment (day 90) 43.3 ± 13.5 56.0 ± 9.0 50.1 ± 8.5 48.3 ± 11.7
4-Week recovery 37.2 ± 23.4 44.5 ± 22.2 36.7 ± 2.0 25.8 ± 7.1
Lymph (%) Acclimation period (day 16) 46.8 ± 18.8 45.0 ± 12.5 45.8 ± 6.0 45.3 ± 10.5
Acclimation period (day 44) 36.7 ± 14.0 42.8 ± 9.2 43.8 ± 10.9 47.6 ± 7.0
Treatment (day 30) 58.3 ± 10.9 44.7 ± 9.8 50.6 ± 10.0 51.5 ± 12.5
Treatment (day 60) 60.6 ± 12.0 55.5 ± 5.6 53.7 ± 6.0 57.9 ± 10.1
Treatment (day 90) 50.3 ± 10.9 39.3 ± 8.3 44.4 ± 7.6 45.9 ± 9.9
4-Week recovery 53.0 ± 17.5 47.8 ± 16.5 57.5 ± 0.4 68.6 ± 7.6
Mono (%) Acclimation period (day 16) 2.3 ± 0.6 2.6 ± 0.8 2.9 ± 0.6 3.1 ± 1.1
Acclimation period (day 44) 2.2 ± 0.6 2.6 ± 0.6 3.3 ± 1.1 3.3 ± 0.7
Treatment (day 30) 2.6 ± 0.8 1.8 ± 0.7 2.6 ± 0.8 2.9 ± 0.8
Treatment (day 60) 1.9 ± 0.3 2.4 ± 1.0 2.3 ± 1.0 2.7 ± 0.7
Treatment (day 90) 2.1 ± 0.7 1.7 ± 0.4 2.8 ± 1.0 2.7 ± 0.3
4-Week recovery 2.2 ± 0.1 2.6 ± 0.8 2.4 ± 0.3 2.3 ± 0.1
Eos (%) Acclimation period (day 16) 2.3 ± 0.8 2.0 ± 0.7 2.1 ± 0.7 2.1 ± 1.3
Acclimation period (day 44) 1.8 ± 1.2 1.7 ± 0.6 2.2 ± 1.6 1.8 ± 1.5
Treatment (day 30) 2.9 ± 1.2 1.9 ± 0.5 2.7 ± 1.5 1.7 ± 1.0
Treatment (day 60) 2.3 ± 1.3 2.2 ± 0.9 2.9 ± 1.5 2.1 ± 1.6
Treatment (day 90) 2.9 ± 2.4 2.0 ± 1.0 1.6 ± 0.6 2.1 ± 1.9
4-Week recovery 6.1 ± 5.7 3.9 ± 4.4 2.2 ± 1.8 2.0 ± 0.6
Baso (%) Acclimation period (day 16) 0.3 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
Acclimation period (day 44) 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.1
Treatment (day 30) 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1
Treatment (day 60) 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
Treatment (day 90) 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1
4-Week recovery 0.3 ± 0.1 0.2 ± 0.0 0.3 ± 0.1 0.5 ± 0.1
PT (s) Acclimation period (day 16) 10.1 ± 0.4 10.6 ± 0.5 10.3 ± 0.6 10.2 ± 0.3
Acclimation period (day 44) 10.1 ± 0.4 10.3 ± 0.2 10.1 ± 0.4 9.9 ± 0.3
Treatment (day 30) 9.9 ± 0.4 10.2 ± 0.9 10.0 ± 0.6 9.8 ± 0.2
Treatment (day 60) 9.8 ± 0.3 9.9 ± 0.3 10.0 ± 0.5 9.7 ± 0.4
Treatment (day 90) 10.1 ± 0.3 10.0 ± 0.3 10.2 ± 0.5 9.9 ± 0.3
4-Week recovery 9.4 ± 0.1 9.6 ± 0.2 9.2 ± 0.3 9.6 ± 0.5
APTT (s) Acclimation period (day 16) 18.4 ± 0.7 19.1 ± 2.0 18.0 ± 1.2 17.9 ± 1.0
Acclimation period (day 44) 18.4 ± 1.4 18.5 ± 2.3 17.9 ± 1.1 17.5 ± 0.9
Treatment (day 30) 17.7 ± 2.0 18.0 ± 1.7 16.9 ± 0.9 16.7 ± 0.6
Treatment (day 60) 18.3 ± 1.0 18.7 ± 1.9 17.5 ± 0.9 18.1 ± 1.3
Treatment (day 90) 18.8 ± 1.1 19.2 ± 2.0 19.4 ± 3.8 17.9 ± 0.4
4-Week recovery 17.6 ± 1.3 20.5 ± 4.2 16.2 ± 0.1 16.7 ± 0.2
CD4+ (%) Acclimation period (day 16) 51.58 ± 10.37 55.64 ± 5.16 54.93 ± 8.20 56.19 ± 10.48
Acclimation period (day 44) 53.83 ± 9.30 57.31 ± 5.44 59.22 ± 4.78 60.55 ± 8.01
Treatment (day 30) 51.37 ± 10.26 57.70 ± 5.59 58.86 ± 8.49 60.14 ± 8.31
Treatment (day 60) 55.85 ± 10.63 56.70 ± 6.46 59.31 ± 6.50 56.83 ± 7.78
Treatment (day 90) 53.33 ± 8.74 57.35 ± 4.40 60.63 ± 6.74 60.59 ± 8.47
4-Week recovery 52.03 ± 6.39 63.79 ± 0.70 56.12 ± 5.12 59.32 ± 18.77
CD8+ (%) Acclimation period (day 16) 41.90 ± 11.91 36.49 ± 7.04 37.83 ± 8.62 34.10 ± 5.47
Acclimation period (day 44) 39.99 ± 10.11 35.43 ± 6.68 33.29 ± 4.89 31.01 ± 4.63
Treatment (day 30) 41.90 ± 10.38 34.20 ± 7.38 33.65 ± 7.30 30.74 ± 5.66
Treatment (day 60) 38.06 ± 10.87 35.52 ± 7.82 33.07 ± 5.56 34.32 ± 6.90
Treatment (day 90) 39.34 ± 9.59 34.33 ± 6.24 31.27 ± 5.58 30.34 ± 5.55
518 L. Guo et al. / Regulatory Toxicology and Pharmacology 69 (2014) 512–523
Table 7 (continued)
Parameters Time M2ES (groups)
Control 3 mg/kg 10 mg/kg 30 mg/kg
4-Week recovery 43.02 ± 5.95 27.81 ± 3.78 36.77 ± 5.54 35.43 ± 18.41
CD4+/CD8+ Acclimation period (day 16) 1.37 ± 0.64 1.60 ± 0.47 1.54 ± 0.45 1.74 ± 0.67
Acclimation period (day 44) 1.45 ± 0.52 1.69 ± 0.48 1.82 ± 0.38 2.02 ± 0.57
Treatment (day 30) 1.35 ± 0.60 1.79 ± 0.60 1.85 ± 0.59 2.06 ± 0.71
Treatment (day 60) 1.62 ± 0.68 1.71 ± 0.60 1.86 ± 0.46 1.76 ± 0.67
Treatment (day 90) 1.48 ± 0.60 1.74 ± 0.48 2.02 ± 0.59 2.10 ± 0.72
4-Week recovery 1.23 ± 0.32 2.32 ± 0.34 1.56 ± 0.37 2.09 ± 1.62
SD: mean ± standard deviation.
* P < 0.05.
Table 8
Clinical chemistry – three-months repeat-dose toxicity study with 4-week recovery.
Parameters Time M2ES (groups)
Control 3 mg/kg 10 mg/kg 30 mg/kg
GLU (mmol/L) Acclimation period (day 16) 4.57 ± 0.78 4.50 ± 0.34 4.77 ± 0.47 4.68 ± 0.83
Acclimation period (day 44) 4.77 ± 1.26 4.84 ± 1.15 5.07 ± 0.63 4.38 ± 0.82
Treatment (day 30) 4.07 ± 0.41 3.57 ± 0.39 3.87 ± 0.55 3.81 ± 0.44
Treatment (day 60) 4.10 ± 0.86 3.69 ± 0.51 4.13 ± 0.63 3.90 ± 0.45
Treatment (day 90) 3.96 ± 0.37 3.68 ± 0.32 4.37 ± 0.49 4.12 ± 0.67
4-Week recovery 4.09 ± 0.13 4.03 ± 0.48 4.13 ± 0.27 3.28 ± 1.39
BUN (mmol/L) Acclimation period (day 16) 5.1 ± 1.7 4.4 ± 1.0 5.1 ± 0.7 4.8 ± 1.0
Acclimation period (day 44) 5.1 ± 2.9 4.3 ± 1.0 4.4 ± 0.6 3.9 ± 0.5
Treatment (day 30) 6.0 ± 2.0 7.0 ± 1.6 7.0 ± 1.2 6.7 ± 0.9
Treatment (day 60) 5.0 ± 0.6 6.2 ± 1.4 5.5 ± 0.4 4.8 ± 0.6
Treatment (day 90) 4.8 ± 0.8 5.6 ± 1.1 5.0 ± 0.9 5.3 ± 0.8
4-Week recovery 5.5 ± 0.6 7.0 ± 2.3 6.0 ± 0.6 6.1 ± 1.0
CRE (lmol/L) Acclimation period (day 16) 54 ± 8 55 ± 10 56 ± 5 56 ± 9
Acclimation period (day 44) 67 ± 13 65 ± 8 68 ± 7 70 ± 10
Treatment (day 30) 67 ± 6 62 ± 6 67 ± 4 67 ± 9
Treatment (day 60) 58 ± 7 54 ± 8 59 ± 7 59 ± 9
Treatment (day 90) 70 ± 7 64 ± 7 67 ± 5 71 ± 10
4-Week recovery 65 ± 2 64 ± 1 72 ± 18 72 ± 1
CHO (mmol/L) Acclimation period (day 16) 2.82 ± 0.55 3.38 ± 0.85 2.71 ± 0.44 3.23 ± 0.88
Acclimation period (day 44) 3.10 ± 0.72 3.38 ± 0.42 2.90 ± 0.48 3.56 ± 0.61
Treatment (day 30) 2.88 ± 0.59 3.08 ± 0.26 2.76 ± 0.25 2.90 ± 0.70
Treatment (day 60) 2.78 ± 0.49 3.11 ± 0.18 2.68 ± 0.21 2.87 ± 0.56
Treatment (day 90) 2.43 ± 0.46 2.63 ± 0.12 2.30 ± 0.21 2.45 ± 0.55
4-Week recovery 2.31 ± 0.06 3.06 ± 0.18 2.63 ± 0.29 3.06 ± 1.39
TG (mmol/L) Acclimation period (day 16) 0.33 ± 0.10 0.26 ± 0.07 0.29 ± 0.11 0.38 ± 0.07
Acclimation period (day 44) 0.34 ± 0.08 0.21 ± 0.05 0.26 ± 0.11 0.32 ± 0.08
Treatment (day 30) 0.33 ± 0.16 0.33 ± 0.15 0.40 ± 0.08 0.36 ± 0.11
Treatment (day 60) 0.38 ± 0.10 0.38 ± 0.14 0.44 ± 0.14 0.41 ± 0.04
Treatment (day 90) 0.46 ± 0.21 0.41 ± 0.14 0.44 ± 0.15 0.44 ± 0.09
4-Week recovery 0.56 ± 0.08 0.59 ± 0.04 0.63 ± 0.23 0.79 ± 0.21
K+ (mmol/L) Acclimation period (day 16) 4.14 ± 0.48 3.85 ± 0.27 4.31 ± 0.49 4.05 ± 0.42
Acclimation period (day 44) 4.17 ± 0.58 4.11 ± 0.26 4.09 ± 0.14 4.26 ± 0.51
Treatment (day 30) 4.24 ± 0.46 3.78 ± 0.25 4.28 ± 0.35 4.26 ± 0.40
Treatment (day 60) 4.40 ± 0.36 3.93 ± 0.20 4.48 ± 0.32 4.48 ± 0.52
Treatment (day 90) 4.55 ± 0.87 4.07 ± 0.39 4.45 ± 0.15 4.36 ± 0.30
4-Week recovery 4.65 ± 0.93 3.78 ± 0.42 3.78 ± 0.42 4.51 ± 0.59
Na+ (mmol/L) Acclimation period (day 16) 145.7 ± 2.4 147.2 ± 3.3 147.8 ± 3.0 147.4 ± 3.2
Acclimation period (day 44) 150.4 ± 2.2 148.7 ± 2.3 150.1 ± 2.4 151.8 ± 2.8
Treatment (day 30) 148.2 ± 1.8 145.4 ± 2.4 147.3 ± 1.4 147.7 ± 1.9
Treatment (day 60) 153.1 ± 2.9 151.4 ± 3.8 152.4 ± 1.8 152.6 ± 2.1
Treatment (day 90) 154.8 ± 2.7 149.9 ± 1.8** 151.8 ± 1.6 152.1 ± 2.6
4-Week recovery 148.7 ± 0.4 147.2 ± 4.0 149.5 ± 1.6 149.8 ± 0.1
Cl (mmol/L) Acclimation period (day 16) 109.8 ± 1.9 110.1 ± 6.3 112.0 ± 1.4 111.4 ± 3.1
Acclimation period (day 44) 116.7 ± 2.3 115.2 ± 3.1 115.8 ± 1.0 116.4 ± 2.6
Treatment (day 30) 113.8 ± 1.6 111.7 ± 2.7 113.2 ± 1.2 114.0 ± 2.1
Treatment (day 60) 107.9 ± 1.5 105.6 ± 1.9 107.6 ± 1.4 107.6 ± 2.1
Treatment (day 90) 108.4 ± 2.4 105.3 ± 2.1 106.8 ± 1.7 105.8 ± 2.6
4-Week recovery 101.9 ± 1.1 101.7 ± 3.5 102.5 ± 0.5 103.4 ± 0.6
ALT (U/L) Acclimation period (day 16) 40 ± 11 34 ± 11 45 ± 13 62 ± 46
Acclimation period (day 44) 63 ± 42 32 ± 7 44 ± 28 36 ± 19
Treatment (day 30) 48 ± 21 31 ± 13 35 ± 24 40 ± 29
Treatment (day 60) 35 ± 14 28 ± 14 30 ± 13 25 ± 12
Treatment (day 90) 47 ± 25 35 ± 21 62 ± 69 40 ± 27
4-Week recovery 53 ± 21 35 ± 6 59 ± 48 26 ± 14
AST (U/L) Acclimation period (day 16) 60 ± 8 53 ± 11 79 ± 27 93 ± 41
Acclimation period (day 44) 73 ± 16 56 ± 9 64 ± 8 72 ± 14
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animals. Consistently, Cmax was reached after 0.5 h, and Ctime grad-
ually decreased in a time-proportional manner in all three dose
groups (Fig. 2B, Table 4). The AUC(0–96) of M2ES (day 87) was
27.2 ± 20.0, 117.5 ± 55.2, and 278.7 ± 110.3 lg h/mL at the 3 dose
levels, respectively (Table 4), and the ratio of dose and the corre-
sponding ratio of AUC(0–96) were 1:3.3:10 and 1:4.3:10.2, respec-
tively, suggesting that AUC of M2ES is positively correlated with
the dosage. In addition, the mean value of Ctime at day 87 was sig-
nificantly higher than that at day 1 (Fig. 2C–E). Three-month
repeated dosing with M2ES in 3, 10, 30 mg/kg resulted in 3.0, 3.3,
and 1.5 folds increase in AUC(0–96) at day 87 compared with day
1 (Tables 3 and 4). Taken together, these results demonstrated that
animals, administered with three-month twice/weekly M2ES,
exhibited the accumulation of M2ES in rhesus monkeys.
3.2. Antibody formation
After 14 days of administration, anti-M2ES antibodies were
detected in 1/6, 4/6, and 1/6 of the animals dosed with M2ES at
3, 10, and 30 mg/kg, respectively (Table 5). After 90 days successive
Table 8 (continued)
Parameters Time M2ES (groups)
Control 3 mg/kg 10 mg/kg 30 mg/kg
Treatment (day 30) 50 ± 9 42 ± 7 47 ± 10 54 ± 8
Treatment (day 60) 51 ± 11 40 ± 4 43 ± 8 50 ± 5
Treatment (day 90) 48 ± 21 38 ± 6 60 ± 15 59 ± 12
4-Week recovery 52 ± 3 41 ± 1 47 ± 1 56 ± 12
TP (g/L) Acclimation period (day 16) 75.3 ± 4.4 75.9 ± 3.8 75.7 ± 3.5 78.7 ± 5.4
Acclimation period (day 44) 77.6 ± 6.7 74.8 ± 3.4 75.3 ± 5.1 79.7 ± 3.8
Treatment (day 30) 74.2 ± 7.2 71.3 ± 3.6 75.1 ± 3.2 74.1 ± 5.8
Treatment (day 60) 75.3 ± 6.1 74.9 ± 3.9 76.3 ± 3.3 77.5 ± 4.4
Treatment (day 90) 78.6 ± 6.4 73.0 ± 3.0 75.4 ± 2.4 76.8 ± 3.3
4-Week recovery 79.1 ± 7.5 73.6 ± 2.1 79.3 ± 6.4 79.1 ± 4.7
ALB (g/L) Acclimation period (day 16) 46.5 ± 6.7 49.1 ± 2.6 48.9 ± 1.5 49.3 ± 2.2
Acclimation period (day 44) 47.1 ± 4.6 47.8 ± 1.9 48.4 ± 2.9 49.7 ± 2.1
Treatment (day 30) 46.8 ± 3.1 47.3 ± 1.0 48.9 ± 1.8 48.9 ± 2.6
Treatment (day 60) 46.3 ± 5.4 47.6 ± 1.7 49.0 ± 1.0 48.9 ± 2.1
Treatment (day 90) 48.5 ± 2.5 46.7 ± 1.2 48.0 ± 1.2 48.7 ± 0.9
4-Week recovery 48.3 ± 2.2 46.6 ± 0.4 49.2 ± 1.6 48.8 ± 0.7
TBIL (lmol/L) Acclimation period (day 16) 5.71 ± 1.95 4.41 ± 1.63 4.53 ± 1.71 4.23 ± 1.37
Acclimation period (day 44) 4.41 ± 1.58 3.26 ± 1.39 3.48 ± 0.99 3.40 ± 1.23
Treatment (day 30) 3.27 ± 0.54 2.68 ± 0.61 2.55 ± 0.39 2.34 ± 0.45*
Treatment (day 60) 4.74 ± 1.43 3.58 ± 1.98 3.70 ± 0.54 2.94 ± 0.96
Treatment (day 90) 8.59 ± 1.71 6.62 ± 2.63 7.44 ± 2.04 5.64 ± 1.20
4-Week recovery 7.41 ± 0.03 4.24 ± 0.11 5.47 ± 0.76 5.99 ± 0.93
ALP (U/L) Acclimation period (day 16) 242 ± 56 325 ± 74 324 ± 73 304 ± 140
Acclimation period (day 44) 261 ± 58 318 ± 60 356 ± 105 359 ± 151
Treatment (day 30) 323 ± 86 315 ± 47 464 ± 141 377 ± 148
Treatment (day 60) 352 ± 104 408 ± 51 519 ± 174 422 ± 143
Treatment (day 90) 322 ± 70 348 ± 31 452 ± 182 371 ± 120
4-Week recovery 271 ± 139 352 ± 66 325 ± 74 287 ± 11
LDH (U/L) Acclimation period (day 16) 271 ± 47 228 ± 32 325 ± 145 327 ± 79
Acclimation period (day 44) 240 ± 40 224 ± 35 243 ± 27 261 ± 33
Treatment (day 30) 230 ± 80 236 ± 59 299 ± 116 245 ± 31
Treatment (day 60) 340 ± 132 279 ± 55 332 ± 103 372 ± 98
Treatment (day 90) 260 ± 46 254 ± 38 347 ± 102 395 ± 104*
4-Week recovery 221 ± 6 209 ± 43 255 ± 32 267 ± 60
CK (U/L) Acclimation period (day 16) 147 ± 85 120 ± 61 228 ± 209 341 ± 353
Acclimation period (day 44) 158 ± 88 112 ± 55 95 ± 16 107 ± 23
Treatment (day 30) 106 ± 77 89 ± 22 79 ± 11 126 ± 61
Treatment (day 60) 105 ± 59 82 ± 31 84 ± 34 101 ± 47
Treatment (day 90) 83 ± 37 69 ± 17 186 ± 157 121 ± 44
4-Week recovery 66 ± 13 80 ± 10 77 ± 16 94 ± 30
SD: mean ± standard deviation.
* P < 0.05.
** P < 0.01.
Table 9
Kidney – three-month repeat-dose toxicity study with 4-week recovery.
Time Groups (mg/kg) Kidney (rhesus monkey)
Left Right
Wt (g) RWt (g/kg) Wt (g) RWt (g/kg)
Administration 0 7.5 ± 0.9 1.9 ± 0.2 7.5 ± 1.2 1.9 ± 0.2
3 8.1 ± 1.3 2.0 ± 0.1 8.3 ± 1.4 2.1 ± 0.1
10 8.2 ± 1.0 2.1 ± 0.2 7.8 ± 1.0 2.0 ± 0.2
30 7.8 ± 0.7 2.0 ± 0.3 7.8 ± 0.6 2.0 ± 0.2
4-Week recovery 0 8.4 ± 0.3 2.2 ± 0.0 8.2 ± 0.2 2.1 ± 0.0
3 7.1 ± 0.5 2.0 ± 0.1 6.9 ± 0.4 2.0 ± 0.1
10 7.5 ± 0.9 2.0 ± 0.1 7.5 ± 0.6 2.0 ± 0.0
30 7.0 ± 1.1 2.1 ± 0.1 7.0 ± 1.5 2.1 ± 0.3
Wt (g): absolute weight; RWt (g/kg): relative kidney weight. SD: mean ± standard deviation.
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IV infusions of M2ES, antibodies could be detected in nearly all rhe-
sus monkeys (17/18) (Table 5). The positive rate of antibody detec-
tion and antibody level did not significantly decrease after four-
week recovery period (Table 5). In addition, after three-month
repeated dosing with M2ES, the serum collected from rhesus mon-
keys could not neutralize the biological activity of M2ES (data not
shown), indicating that M2ES-induced antibody in the serum is
non-neutralizing.
3.3. Safety evaluation in rhesus monkeys
In the three-month repeat-dose toxicity study, four groups of
six rhesus monkeys (half males and half females) received saline
or 3, 10, 30 mg/kg M2ES twice weekly by IV infusions. M2ES was
well tolerated in animals, with no observable changes in clinical
observations (Table 6), body weight (Fig. 3), food consumption,
urine analysis, body temperature, and ECG (data not shown). In
addition, the hematological (Table 7) and clinical chemistry param-
eters (Table 8) were found to be in normal range in all the blood
samples collected during the three months repeat-dose toxicity
study with four-week recovery period.
After euthanasia by exsanguination, all rhesus monkeys had a
complete necropsy evaluation, and histopathological analysis.
There were no effects on organ weights or frommacroscopic exam-
ination. (Table 9 and data not shown). However, in animals admin-
istered IV injections of M2ES at 10 and 30 mg/kg body weight twice
weekly for three months, mild to moderate vacuolation of proxi-
mal tubule epithelial cell in the proximal convoluted tubule of kid-
ney was observed (Fig. 4A and B and Table 10) and incidence was
1/4 and 3/4, respectively. After four-week recovery period, the
symptoms were obviously alleviated (Fig. 4C and D). Animals trea-
ted with 10 mg/kg twice weekly revealed slight vacuolation of
proximal tubule epithelial cell (incidence 1/2). Animals received
30 mg/kg twice weekly revealed mild vacuolation of proximal
tubule epithelial cell (incidence 1/2), suggesting that high-dose
M2ES-induced vacuolation of proximal tubule epithelial cell is
reversible.
4. Discussion
In this study we evaluated the kinetics and toxicity of M2ES in
Rhesus monkeys. In the GLP-compliant study, animals adminis-
tered with three-month twice/weekly M2ES exhibited M2ES accu-
mulation, anti-M2ES antibodies formation, and mild or moderate
vacuolation of proximal tubule epithelial cell in proximal convo-
luted tubule of kidney, but this toxicity reaction was reversible.
Endostatin, a well-documented endogenous inhibitor of angio-
genesis, was discovered by O’Reilly et al. (1997). Although its struc-
ture, function, and molecular mechanism have been extensively
investigated, the clinical effectiveness of endostatin has been varied
(Fu et al., 2009; Khan et al., 2006). Endostatin expressed by Pichia
pastoris (Entered, Rockville, MD) failed during phase II clinical test-
ing for its poor efficacy and production problems (Whitworth,
2006); whereas YH-16 (Medgenn Ltd., Yantai, China), a modified
Fig. 4. H&E staining of kidney sections in (A) control, (B) after three-months repeat-dose of M2ES (10 mg/kg), (B0) the magnified image of the boxed region (Fig. 3B), (C) after
three-months repeat-dose of M2ES (30 mg/kg), (C0) the magnified image of the boxed region (Fig. 3C), and (D) after four-week recovery period (Re-M2ES 30 mg/kg). Original
magnification: 200, Mag. 400.
Table 10
Vacuolation of proximal tubule epithelial cell – three-month repeat-dose toxicity
study with 4-week recovery.
Time Groups
Control M2ES (3 mg/kg) M2ES (10 mg/kg) M2ES (30 mg/kg)
Treatment 0/4 1/4* 1/4** 3/4***
4-Week recovery 0/4 0/2 1/2* 1/2**
a/b: first number indicates positive animal number; second number indicates total
animal number.
* Slight vacuolation of proximal tubule epithelial cell.
** Mild vacuolation of proximal tubule epithelial cell.
*** Moderate vacuolation of proximal tubule epithelial cell.
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human endostatin with a nine amino acid sequence at the N-termi-
nus (MGGSHHHHH), expressed by E. coli, was approved by the
CFDA for good clinical responses (Cui et al., 2013; Han et al.,
2011). To explain this difference, we analyzed the structure of P.
pastoris-expressed and E. coli-expressed endostatin, and found that
almost 93% of P. pastoris-expressed endostatin was truncated and
lost its zinc binding capacity. This truncated form contributed to
reduced stability and lowered anti-tumor capacity. However,
endostatin expressed by E. coliwas proved to be an intact molecule
with full anti-angiogenic activity (Fu and Luo, 2010). Therefore,
M2ES used in this study was PEGylated E. coli-expressed endostatin.
Based on our results, we compared the main pharmacokinetic
parameters of M2ES with those of YH-16 in rhesus monkeys. After
single dose of M2ES or YH-16, the half-life (T1/2) of M2ES (3 mg/kg)
was significantly longer than that of YH-16 (4.5 mg/kg) (8.5 ± 9.8 h
vs. 0.04 ± 0.03 h) (Song et al., 2005). Intriguingly, both M2ES [T1/2 of
M2ES (3 mg/kg, day 1) was 8.5 ± 9.8 h, T1/2 of M2ES (3 mg/kg, day
87) was 24.4 ± 19.4 h] and Yh-16 had a tendency to accumulate
in the animal body after successive IV administrations, but this
phenomenon was not observed in E. coli-expressed endostatin
(Hu et al., 2008). As for serum antibodies to M2ES, we found that
anti-M2ES antibodies were generated quickly during IV adminis-
tration, and the antibody level did not significantly reduce after
four-week recovery period. On the contrary, anti-endostatin anti-
bodies decreased rapidly after treatment (Hu et al., 2008). Previous
reports indicated that the primary target organ of PEG or PEGylated
proteins at high doses was kidney (Bendele et al., 1998; Rudmann
et al., 2013). Consistently, after IV infusions of M2ES (10 or 30 mg/
kg) for three month, we observed mild or moderate vacuolation of
proximal tubule epithelial cell in proximal convoluted tubule. In
addition, kidneys from rhesus monkey on periodic acid-schiff
(PSA) stain had hydropic degeneration but no immune complex
deposition in tubular basement membranes (unpublished data),
indicating that vacuolation of proximal tubule epithelial cell was
not caused by the deposition of antibody protein complexes. Since
there was no detectable side-effect in kidney after YH-16 [N-termi-
nus (MGGSHHHHH) modified endostatin not associated with PEG]
treatment (Huang et al., 2012), the reversible side-effect in kidney
may be associated with PEG. Previously, some clinical trials had
shown that endostatin might cause side-effects in the cardiovascu-
lar system (Jing et al., 2008). In this study, we did not observe sig-
nificant changes in ECG after M2ES treatment. Considering the
individual difference of rhesus monkeys and sensitivity of EGC,
ECG test alone could not fully verify that M2ES had no potential
cardiotoxic reaction. We should have used implantable telemetry
or jacketed external telemetry system. Since pre-clinical toxicoki-
netics and safety study of M2ES in rhesus monkeys were performed
in 2006, telemetry system was not available in China at that time.
In addition, the phase I clinical trial of M2ES preliminary data
showed that M2ES had little effect on cardiotoxicity in non-small
cell lung cancer patients (dose levels include 7.5, 10.0, 12.5,
15 mg/m2. Dosing duration is 2 h).
5. Conclusions
This pre-clinical toxicokinetics and safety study of M2ES dem-
onstrated that treatment with M2ES at evaluated dose was feasible,
without causing obvious toxicity in rhesus monkeys. Based on the
absence of any overt side-effect in the animal studies presented
here and other pre-clinical data (hemolytic assay, active systemic
anaphylaxis (ASA) in guinea pigs, acute toxicity in mice, acute
toxicity in rhesus monkey, long-term toxicity test in rats, long-
term toxicity test in rhesus monkeys, safety pharmacology tests
in mice, safety pharmacology tests in rhesus monkeys, pre-clinical
efficacy of M2ES, pre-clinical pharmacokinetics and toxicokinetics
of M2ES in rats, characterization of M2ES) (unpublished data),
CFDA approval has been granted to initiate a phase I clinical trial
with M2ES for the treatment of patients with non-small lung
cancer.
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